BrightPath Biotherapeutics Co., Ltd. engages in the development of cancer immunotherapy drugs in Japan. The company is developing BP2201, a product candidate in Phase I clinical trials to target cancer antigens in various types of cancer; BP2202, Phase I clinical trial to target cancer; and BP2301, a product candidate in Phase I clinical trials for the treatment of solid tumors sarcoma and gynecological cancers. In addition, its product candidates in preclinical trials include BP1200 that targets CD73; BP1202 that targets acute myeloid leukemia; BP1210, which suppresses T cell cytotoxicity; BP1212 to inhibit TIM-3 and CD39; BP1209 to target tumor-specific neo-antigens; and BP1223 to target blood cancers. The company was formerly known as GreenPeptide Co., Ltd. and changed its name to BrightPath Biotherapeutics Co., Ltd. in July 2017. The company was incorporated in 2003 and is headquartered in Kawasaki, Japan.
Frequently asked questions
What sector does BrightPath Biotherapeutics Co Ltd (4594) operate in?
BrightPath Biotherapeutics Co Ltd belongs to the Healthcare sector and operates in the Biotechnology industry.
What is BrightPath Biotherapeutics Co Ltd (4594) current stock price?
As of the latest data, BrightPath Biotherapeutics Co Ltd stock price is ¥48, with a previous close of ¥48.
What is BrightPath Biotherapeutics Co Ltd (4594) current market capitalization?
BrightPath Biotherapeutics Co Ltd market cap is approximately 6.67 billion.
What is BrightPath Biotherapeutics Co Ltd (4594) Earnings Per Share (EPS)?
The trailing EPS is -¥12.
What is BrightPath Biotherapeutics Co Ltd (4594) EBITDA?
BrightPath Biotherapeutics Co Ltd EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -547.07 million.
Does BrightPath Biotherapeutics Co Ltd (4594) pay dividends?
No. BrightPath Biotherapeutics Co Ltd does not pay a dividend.
What is BrightPath Biotherapeutics Co Ltd (4594) beta (volatility) score?
BrightPath Biotherapeutics Co Ltd has a beta of 1.301, suggesting it is more volatile than the market.
